TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion

  • Authors:
    • Hou-Gen Lu
    • Wang Zhan
    • Lin Yan
    • Rui-Ying Qin
    • Yi-Peng Yan
    • Zhen-Jiang Yang
    • Gui‑Chao  Liu
    • Gui-Qin Li
    • Hai-Feng Wang
    • Xing-Liang Li
    • Zhi Li
    • Lu Gao
    • Guo-Qing Chen
  • View Affiliations

  • Published online on: August 26, 2014     https://doi.org/10.3892/mmr.2014.2517
  • Pages: 2595-2600
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Histone deacetylases (HDACs) are important in chromatin remodeling and epigenetic regulation of gene expression. Histone deacetylase inhibitors (HDACi) have highly effective anti-metastatic and anti-angiogenic activity in various types of cancer, while the molecular mechanisms involved in this process are not fully understood. In the present study, trichostatin A (TSA), a HDACi, was found to suppress MCF-7 breast carcinoma cell invasion and upregulate TET1 expression in a dose-dependent manner. TET1, a dioxygenase involved in cytosine demethylation, is downregulated during breast cancer progression. TET1 knockdown in MCF-7 cells facilitates cell invasion, inhibits the expression of tissue inhibitors of metalloproteinase 2/3 (TIMP2/3) and promotes matrix metalloproteinases (MMP) 2/9 transcriptional activity. Importantly, TET1 depletion impaired the inhibitory effect of TSA on breast cancer cell invasion. Together, these results illustrated a mechanism by which TET1 partially mediates HDACi elicited suppression of breast cancer invasion.

References

1 

Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Mohanam S, Sawaya R, McCutcheon I, Ali-Osman F, Boyd D and Rao JS: Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 53:4143–4147. 1993.PubMed/NCBI

3 

Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 3:489–501. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI

5 

Horikoshi M: Histone acetylation: from code to web and router via intrinsically disordered regions. Curr Pharm Des. 19:5019–5042. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Gräff J and Tsai LH: Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci. 14:97–111. 2013.PubMed/NCBI

7 

Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y and Jones DR: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem. 278:18980–18989. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Brochier C, Dennis G, Rivieccio MA, McLaughlin K, Coppola G, Ratan RR and Langley B: Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J Neurosci. 33:8621–8632. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Sachweh MC, Drummond CJ, Higgins M, Campbell J and Laín S: Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis. 4:e5332013. View Article : Google Scholar : PubMed/NCBI

10 

Cheung WL, Briggs SD and Allis CD: Acetylation and chromosomal functions. Curr Opin Cell Biol. 12:326–333. 2000. View Article : Google Scholar : PubMed/NCBI

11 

Van Lint C, Emiliani S and Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5:245–253. 1996.PubMed/NCBI

12 

Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 101:540–545. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Song J, Noh JH, Lee JH, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 113:264–268. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004. View Article : Google Scholar : PubMed/NCBI

15 

Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res. 91:137–168. 2004. View Article : Google Scholar : PubMed/NCBI

16 

McGarry LC, Winnie JN and Ozanne BW: Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene. 23:5284–5292. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Marks PA, Richon VM, Kelly WK, Chiao JH and Miller T: Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp. 259:269–281. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Vigushin DM, Ali S, Pace PE, et al: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 7:971–976. 2001.

19 

Tarasenko N, Nudelman A, Tarasenko I, et al: Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis. 25:703–716. 2008. View Article : Google Scholar

20 

Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 5:769–784. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Liu LT, Chang HC, Chiang LC and Hung WC: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63:3069–3072. 2003.PubMed/NCBI

22 

Hsu CH, Peng KL, Kang ML, et al: TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Yang H, Liu Y, Bai F, et al: Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 32:663–669. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Asrani K, Keri RA, Galisteo R, et al: The HER2- and heregulin beta1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Mol Cancer Res. 11:393–404. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Brown SA, Ghosh A and Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 285:17432–17441. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Grimaldi C, Pisanti S, Laezza C, et al: Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res. 312:363–373. 2006. View Article : Google Scholar : PubMed/NCBI

27 

Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI

28 

Baker AH, George SJ, Zaltsman AB, Murphy G and Newby AC: Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 79:1347–1355. 1999. View Article : Google Scholar : PubMed/NCBI

29 

Jinga D, Stefanescu M, Blidaru A, Condrea I, Pistol G and Matache C: Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors. Roum Arch Microbiol Immunol. 63:141–158. 2004.PubMed/NCBI

30 

Sier CF, Kubben FJ, Ganesh S, et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 74:413–417. 1996. View Article : Google Scholar

31 

Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar

32 

Taby R and Issa JP: Cancer epigenetics. CA Cancer J Clin. 60:376–392. 2010. View Article : Google Scholar : PubMed/NCBI

33 

Cai FF, Kohler C, Zhang B, Wang MH, Chen WJ and Zhong XY: Epigenetic therapy for breast cancer. Int J Mol Sci. 12:4465–4487. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Namdar M, Perez G, Ngo L and Marks PA: Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA. 107:20003–20008. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Liu T, Kuljaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev. 32:157–165. 2006. View Article : Google Scholar : PubMed/NCBI

36 

Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG and Davidson NE: Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61:7025–7029. 2001.

37 

Travaglini L, Vian L, Billi M, Grignani F and Nervi C: Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol. 41:225–234. 2009. View Article : Google Scholar : PubMed/NCBI

38 

Kim SH, Kang HJ, Na H and Lee MO: Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein. Breast Cancer Res. 12:R222010. View Article : Google Scholar

39 

Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C and Brancolini C: Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem. 278:12579–12589. 2003. View Article : Google Scholar

40 

Williams K, Christensen J, Pedersen MT, et al: TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature. 473:343–348. 2011. View Article : Google Scholar : PubMed/NCBI

41 

Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol. 625:131–142. 2009. View Article : Google Scholar : PubMed/NCBI

42 

Hatziapostolou M and Iliopoulos D: Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 68:1681–1702. 2011. View Article : Google Scholar : PubMed/NCBI

43 

Chik F and Szyf M: Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis. 32:224–232. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November 2014
Volume 10 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lu, H., Zhan, W., Yan, L., Qin, R., Yan, Y., Yang, Z. ... Chen, G. (2014). TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Molecular Medicine Reports, 10, 2595-2600. https://doi.org/10.3892/mmr.2014.2517
MLA
Lu, H., Zhan, W., Yan, L., Qin, R., Yan, Y., Yang, Z., Liu, G., Li, G., Wang, H., Li, X., Li, Z., Gao, L., Chen, G."TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion". Molecular Medicine Reports 10.5 (2014): 2595-2600.
Chicago
Lu, H., Zhan, W., Yan, L., Qin, R., Yan, Y., Yang, Z., Liu, G., Li, G., Wang, H., Li, X., Li, Z., Gao, L., Chen, G."TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion". Molecular Medicine Reports 10, no. 5 (2014): 2595-2600. https://doi.org/10.3892/mmr.2014.2517